Report Code: A13210 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Moyamoya Disease Market Overview 2030
Moyamoya disease (MMD) is defined as a chronic cerebrovascular disease characterized by progressive stenosis of the internal carotid artery and abnormal vascular network at the base of the brain. Stroke is one of the important symptoms of moyamoya disease. It can also cause paralysis of the arms, face and legs, language impairment and temporary loss of nerve function of parts of the body. This can occur in any age but more chances in 5-10 years child and 30-50 years in adults. Antiplatelet agents, anticoagulants, and hematologic agents are used for treatment of moyamoya disease.
COVID-19 Impact Analysis            Â
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the moyamoya disease market.
Top Impacting Factors
Market Trends
New Product Launches to Flourish the Market
In 2020, Johnson & Johnson announced launch of Cerenovus Stroke Device. This product help to aid physicians in clot removal and surgery of cerebrovascular disease such as moyamoya disease.
In 2019, Valenta Pharma announced launch of new generation antioxidant for treatment of cerebrovascular failure named as Ethoxidol. This product can be used in treatment cerebrovascular disease such as moyamoya disease in brain.
In 2019, Boston Scientific Corporation announced U.S. FDA approval for launch of EXALT model D single use deudenoscope. This product can be used in surgery of brain related to moyamoya diseases and other neurological disease.
Key Benefits of the Report
Questions Answered in the Moyamoya Disease Market Report                 Â
Moyamoya Disease Market Report Highlights
Aspects | Details |
---|---|
By Diagnosis |
|
By Treatment |
|
By Distribution Channel |
|
By Region |
|
Key Market Players | AstraZeneca, Pfizer Inc., Johnson and Johnson Services Inc., Novartis AG, Merck Sharp & Dohme Corp., Zimmer Biomet, GlaxoSmithKline plc., Boehringer Ingelheim International GmbH, Abbott, Abiogen Pharma S.p.A., Regeneron Pharmaceuticals Inc., AbbVie Inc., Ampio Pharmaceuticals Inc., Eli Lilly and Company |
Loading Table Of Content...
Start reading.
This Report and over 71,274+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers